I worked during my entire breast cancer treatment. I didn’t want to. I had to. I live alone. I don’t have a husband or boyfriend. I pay my bills on time and by myself. Yes, it was a choice, but it was a horrible one.
I hope I can write this column without crying. Or at least if I do get emotional, that I won’t need to stop a million times while I wait for the sobbing to ease up so that I can see clearly enough to continue typing. And no, I’m not being dramatic.
Breast cancer made my hair thicker. And wavy-er. Not right away obviously. It’s not like it was a special prize I was gifted with to make up for the shock and fear of being diagnosed with breast cancer.
The risk of a COVID-19 diagnosis for breast cancer patients is still not completely known. Studies have come that show that cancer patients are more at risk of adverse effects if they develop COVID-19. However, a few studies state that compared to other cancer patients, breast cancer patients are at a lower risk of serious illness. The stage of breast cancer also seems to play a role in one’s risk level.
Breast cancer prepared me for COVID. Actually, if I want to be really accurate, radiation prepared me for it and almost everything else that has come courtesy of the global pandemic.
Hair loss is something that some women who are diagnosed with breast cancer face. Hair can be a huge part of a person’s identity, especially for a woman. The way your hair looks can communicate a lot to others about the type of person you are. Therefore, it’s understandable that losing your hair following a breast cancer diagnosis can add distress to an already devastating situation. In order to bring some relief and sense of control should you have to deal with hair loss, we outline why and when hair loss occurs as well as things that you can do to get through it.
We all, at some point, need to take on the role of caregiver. For some of us, that time coincides with us needing care as well. At a time when my husband was recovering from heart surgery and anticipating a kidney transplant, where I was to be his donor, I was diagnosed with breast cancer. My surgery was scheduled quickly, and I was spared the ordeal and trauma of radiation and chemotherapy, which I am forever grateful for. However, the emotional toll it took was immeasurable.
I am a 43-year-old mother of two amazing children, I have been in love with my wonderful Martin for 20 years now and I am a research professional in the health sector. Until August 2018, I was considered a breast cancer survivor. My cancer had been treated in the best way possible. My son was not yet one year old at the time (in 2012). I went through chemotherapy, radiotherapy, hormone therapy, a mastectomy and, finally, a breast reconstruction.
CBCN had the opportunity to join researchers, clinicians, manufacturers and other patients at this annual European conference to learn the latest insights and findings in cancer research. Here’s the research that we found most interesting as breast cancer patients:
I remember sitting in the small room waiting for the doctor to come in. I was nervous but didn’t think anything was wrong. The doctor came in and asked how I was. I gave my usual cheery response that everything was good but added that “it depended on what he was going to tell me…ha ha ha”. I laughed but my jovial manner quickly subsided when my doctor sat down and the words “it’s not good” came out. My heart dropped. He then said, “It’s cancer”. My heart dropped again.
Last month, we had the opportunity to attend the 2018 San Antonio Breast Cancer Symposium (SABCS). Here’s some of the key highlights to come out of the conference.
In June 2015, I moved to London, Ontario and was recovering from a rather emotional and difficult time, having divorced in June 2014. I had moved from Sault Ste. Marie to be closer to my daughter with her husband and very young children. I would be seeing the rest of my family less often now – my parents, my two sisters, my daughter and her husband, and another granddaughter. and two step grandchildren.
Tell us a little bit about yourself, where you’re from, and your experience with breast cancer.
Last month, we connected with Alan from ODANO, the Oncology Drug Access Navigators of Ontario, to answer a few questions about who they are and how they help patients in Ontario access life-saving medications.
In August 2014 I found a lump in my left breast. This is unusual for inflammatory breast cancer (IBC), a rare and very aggressive cancer where cancer blocks the lymph vessels.
Inflammatory breast cancer (IBC) is a rare and aggressive form of the disease that doesn’t get a lot of attention. It’s tough to diagnose because of its unusual symptoms, and it’s more common in young women which makes it particularly tricky since the symptoms mimic that of mastitis, a common breast infection in new moms who breastfeed. Here’s what you need to know:
“Abject terror floating in the back of my head.” That’s how Shelley Moore of St. Albert, Alberta describes her reaction to her 2014 diagnosis of Stage II triple negative breast cancer.
Biosimilar therapies have already been in use in Canada for a few years, mostly in the chronic disease and supportive care settings. But soon they will be used for treating cancer as well. There isn’t a lot of information about these new oncology biosimilars and it’s important that breast cancer patients are aware of how their treatment plans may be impacted by these new therapies. We explore some of the emerging biosimilar therapies that will be used to treat cancer patients soon.
Earlier this month, the annual meeting for the American Society of Clinical Oncology was held in Chicago. Here, key research developments in every area of cancer care are shared with oncology professionals from around the world. We’ve compiled the top breast cancer highlights to come out of this year’s ASCO 2018 conference:
Now that you’ve learned more about biosimilars, it may also be of interest to learn what the physician perspective is. We connected with Dr. Sandeep Sehdev, a medical oncologist at the Ottawa Hospital, to get his perspective on biosimilars and what he thinks is important for patients to understand about them.